Pharos Vaccine Inc. is a pioneering BIO venture company
leading development of a unique concept of vaccine for emerging animal diseases and also a cutting-edge
immune cell therapy for human cancers and incurable diseases with relevant platform technologies and capabilities.
Pharos Vaccine Inc. is a pioneering BIO venture company,
leading the development of unique concept of vaccines
for emerging animal diseases and also cutting-edge immune cell therapies for
human cancers and incurable diseases with relevant platform technologies and development capabilities.
Lighting the New Paradigm of Vaccine
Pharos, one of the Seven Wonders of the World, was the world’s first lighthouse and was built on the Egyptian island of Pharos around 280 BC. Like a lighthouse that guides you in the right directions even in bad weather and darkness, Pharos Vaccine will be a true “Pharos” that illuminates the right path with new paradigm, advanced bio-pharmaceuticals led by researchers who have worked in the field of cell and gene therapies for about 20 years.
Lighting the New Paradigm of Animal Medicine
Pharos Vaccine has been performing research and development of vaccines, immuno-therapeutics, and the other bio-medicines to prevent and care veterinary diseases, which affect seriously industry and society, based on bioscience and bioengineering. Experts, who have 30 years of experience in the biotechnology, are developing new paradigm veterinary medicines to become a real lighthouse (Pharos) that lights up the right way toward a happy society for animals and humans as well.
New Paradigm of Therapies
The first-generation cytotoxic anticancer therapies and the second-generation molecular targeting therapies to treat various cancers have shown serious adverse effects that negatively affect normal cells and underachieving efficacy. To this end, the medical sciences urgently demand the development of cell and gene therapies that stimulate the immune system to treat intractable diseases such as blood cancers and other malignant tumors as the third-generation anticancer drugs for high treatment efficacy and improved life quality.
Therapeutic Vaccines based on Immune System
Pharos Vaccine focuses on research and development of immunotherapeutic vaccines that eliminate antigens that cause various cancers and intractable diseases, destroy infected cells, and suppress metastasis and relapse.
Commercializing Cell Therapy Products
Pharos Vaccine is a pioneer of developing and commercializing advanced bio-pharmaceuticals that represent cell and gene therapies to treat a variety of cancers including leukemia, lymphoma, hepatocellular carcinoma, and chronic liver cancer, and intractable diseases such as chronic hepatitis and heart failure following acute myocardial infarction by using immune cells such as tumor-specific T cells, chimeric antigen receptor T (CAR-T) cells, and dendritic cells.
Commercializing Veterinary Vaccine
Pharos Vaccine has been developing veterinary recombinant protein vaccines using immunogenicity enhanced chimeric protein developed by utilizing the company’s distinguishing platform technology. The most veterinary vaccines use the pathogens, e.g. virus, as immunogen, which leads to decreased efficacy due to mutations and safety issues due to live pathogen. Chimeric recombinant proteins have immunogenicity but no pathogenicity, which makes it safe, and mutations can be rapidly reflected to allow efficient reaction to disease. Pharos Vaccine has developed and obtained approval for a foot-and-mouth disease vaccine using chimeric recombinant proteins and is on the way to commercialization, and various other veterinary vaccines are under research and development with the application of this technology.